A Phase 1, Non-randomized, Parallel-group, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Latest Information Update: 14 Dec 2023
At a glance
- Drugs CB-618 (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Cubist Pharmaceuticals
Most Recent Events
- 07 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jan 2015 New trial record